Preparing For Battle: PCSK9 Sponsors Stake Their Ground
Executive Summary
The strong efficacy and sound safety data coming out of the Phase III programs presented at ACC have all eyes on the commercial opportunity for the PCSK9 inhibitor class. Ongoing outcomes trials and market impact of new cholesterol guidelines sparked discussion, and leading sponsors Amgen and Sanofi/Regeneron talked about the potential populations and differences in the devices and dosing of evolocumab and alirocumab.
You may also be interested in...
Educational Efforts Are First Front Of Marketing Battle For PCSK9s
With reams of PCSK9 data showing robust lowering of LDL – a trusted surrogate – under their belt, sponsors aim to win over prescribers, payers and patients ahead of outcomes trial releases.
Amgen’s Evolocumab At FDA: Dawn Of PCSK9 Era Still Cloudy
Firm files BLA for eagerly-awaited PCSK9 inhibitor for high cholesterol, amid continued uncertainty on surrogate markers in cardiovascular trials; Amgen’s heart failure drug ivabradine now has priority review status from FDA and could help pave the way for evolocumab.
Amgen’s Evolocumab At FDA: Dawn Of PCSK9 Era Still Cloudy
Firm files BLA for eagerly-awaited PCSK9 inhibitor for high cholesterol, amid continued uncertainty on surrogate markers in cardiovascular trials; Amgen’s heart failure drug ivabradine now has priority review status from FDA and drug could help pave the way for evolocumab.